Annolyse
BriefingsCompaniesScreenerInsightsPrinciplesCompareChatWatchlist

Explore

  • Briefings
  • Companies
  • Screener
  • Insights
  • Compare

Resources

  • Search
  • Methodology

© 2026 Annolyse.

ChartsAnalysisChatData
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources
←Back to briefings
Oceania Healthcare (OCA) / HY24

NPAT swung to NZ$35.2m but trade debtors expanded NZ$110.5m

Underlying EBITDA held near NZ$37.6m, but receivables expanded NZ$110.5m and debtor days hit 168.5 against a historical mean of 22.7 days.

Healthcare / Retirement living

OCA revenue trajectory

Revenue context before the current result.

↗
Loading chart...
HY24 was $131.6m, versus $122.1m in HY23.

OCA operating cash flow

Operating cash flow across covered periods.

↗
Loading chart...
HY24 was $48m, versus $31.4m in HY23.

OCA working-capital movement

Operating working-capital absorption or release by reporting period.

↗
Loading chart...
HY24 was $110.5m, versus $86.9m in FY23.

OCA NPAT trajectory

Statutory profit after tax across covered periods.

↗
Loading chart...
HY24 was $35.2m, versus $11.2m in HY23.

Market context

Valuation

A close-dated read on what the market price implies next to the latest verified filing inputs. Unavailable metrics stay visible when the absence is useful context.

Prices as at close, 8 June 2026

Price and market cap

The latest close and share count context for the market price.

Market cap

$539.6m

i

End-of-day close multiplied by current shares on issue.

Profitability multiples

How the market price compares with recent earnings and cash-flow inputs.

P/E

10.3x

i

Recent market cap compared with trailing earnings.

EPS

0.07

i

Recent filing-derived earnings per share.

PEG

Not available

i

Not available for this company right now.

EV/EBITDA

12.92x

i

Enterprise value compared with recent EBITDA.

P/FCF

Not available

i

Not meaningful when free cash flow is negative or unavailable.

P/B

0.47x

i

Market value compared with latest reported equity.

Income and fund shape

Yield and fund-style valuation where the company shape supports it.

Dividend yield

0.0%

i

Trailing dividends compared with the latest close.

Total return

Not available

i

Available once dividend and adjustment data are verified.

Release date
22 November 2023
Published
22 April 2026
Ask about this result
Sections⌄
  1. Charts
  2. Valuation
  3. Analysis
  4. Chat
  5. Data
  6. Sources

Key metrics

Numbers worth scanning first

HY24 vs HY23

Revenue

$131.6m

-24.0% ↓ vs $173.3m

EBITDA

$37.6m

— vs —

Net profit after tax

$35.2m

+246.1% ↑ vs −$24.1m

Net cash inflow from operating activities

$48m

+102.5% ↑ vs $23.7m

Declared dividend per share

0.0c

Suppressed: metric quality flags mark this value as unsuitable for normal comparison.

Profit before tax

$32.4m

+199.7% ↑ vs −$32.5m

Cash and cash equivalents

$10.3m

-43.6% ↓ vs $18.3m

Total assets

$2.7b

+8.7% ↑ vs $2.5b

What changed

Trade debtors expanded from NZ$11.0m to NZ$121.5m, lifting debtor days to 168.5 against Annolyse's historical baseline of 22.7 days (range 11.5–28.6) — a working-capital movement well outside the supplied historical pattern

Against that balance-sheet backdrop, profit before tax swung from a NZ$32.5m loss to a NZ$32.4m profit (+199.5%), and net profit after tax recovered to NZ$35.2m (+245.7%).

Headline revenue fell 24.0% to NZ$131.6m, but management reports operating revenue up roughly 8% versus a comparable NZ$122.1m base — the statutory decline reflects lower development and resale gains included in HY23's revenue line. Underlying EBITDA was NZ$37.6m, broadly in line with HY23's NZ$38.7m. Operating cash flow doubled to NZ$48.0m, capex collapsed 79.0% to NZ$23.8m, and pre-lease free cash flow swung to NZ$24.2m. The interim dividend was cut to nil from 1.25 cents.

What matters

Receivables expansion is the main concern

Trade debtors at NZ$121.5m and debtor days of 168.5 sit far outside the company's historical range. Without disclosure on composition, the most likely explanation is settled-but-uncollected village resales sitting in receivables, which means the reported NZ$48.0m operating cash inflow likely draws on legacy ORA receipts rather than current period revenue conversion.

The statutory revenue decline is misleading. Operating revenue actually grew 8% to NZ$131.6m on management's comparable basis; the 24.0% headline drop reflects lower realised gains on development and resales included in HY23's revenue. Total sales volumes were up 13% and new sale volumes up 38%, which supports an underlying volume story rather than a demand collapse.

Leverage worsened and the dividend was withdrawn. Gross borrowings rose to NZ$621.4m, net debt to NZ$611.1m, and cash fell to NZ$10.3m. The board cut the interim dividend to nil and rebased its policy to 30–50% of underlying NPAT (from underlying EBIT). Balance-sheet flexibility, not operating profit, is now the binding constraint.

Expectations

No forward guidance or stated targets were disclosed

The supplied seasonality pattern is heavily second-half-weighted: HY23 represented 70.1% of FY23 revenue but -156.2% of FY23 NPAT, meaning the prior H1 loss was more than offset by H2 settlement gains. On that pattern, HY24's NZ$32.4m PBT already exceeds FY23's full-year NPAT of NZ$15.4m.

The more important second-half question is whether the NZ$121.5m receivable balance converts to cash. That, rather than reported earnings, will set FY24 net debt and the path to dividend resumption under the new policy.

Quality of result

The profit recovery is partly real and partly mix-driven

Underlying EBITDA of NZ$37.6m essentially matched the prior period, so the swing to a NZ$32.4m PBT is driven by lower non-cash fair-value movements on investment property rather than operating expansion. The effective tax rate of -8.6% added a tax credit, so PBT growth of 199.5% is the cleaner read on operating performance than NPAT growth of 245.7%.

Cash quality is where the result is weakest. Pre-lease free cash flow of NZ$24.2m is driven almost entirely by capex collapsing from NZ$113.3m to NZ$23.8m as Oceania completes its development pipeline, not by operating cash generation. Reported operating cash conversion of 127.6% of underlying EBITDA looks healthy in isolation, but trade debtors rose NZ$110.5m over the same window — meaning collections against current revenue were materially below 100% before favourable ORA cash receipts closed the gap. ROE of 3.5% is barely meaningful given the swing nature of the result.

Unresolved

Open questions

What is the composition of the NZ$121.5m trade debtor balance, and how much represents settled-but-uncollected village resales versus other items?
How much of the NZ$48.0m operating cash inflow came from new ORA receipts versus collections against existing balances?
Why did debtor days move from 11.5 to 168.5 — is this a presentation change, settlement timing, or operational deterioration?
When does management expect to return to a paying dividend under the new 30–50% NPAT policy?
How sustainable is the 79.0% capex cut once the current development pipeline rolls off?

This briefing cannot assess the composition of the trade debtor balance or the timing of expected settlement collections without supplementary disclosure.

Chat

Ask about OCA HY24

Ask follow-up questions about Oceania Healthcare's HY24 result.

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Ask about OCA HY24

Informational only. No buy, sell, hold, price-target, or personal financial advice.

Sign in to chat

Sign in to ask questions about Oceania Healthcare's HY24 result.

What is the composition of the NZ$121.5m trade debtor balance, and how much represents settled-but-uncollected village resales versus other items?Why does "Receivables expansion is the main concern" matter?How strong was the cash and earnings quality in HY24?What should I watch next for OCA after HY24?

Checking account...

Data appendix

Show segment detail

Open to load segment breakdown.

Show analytical metrics

Open to load analytical metrics.

Show key metrics table

Open to load key metrics.

Sources

Current period

Interim Report

HY24 / financial report↗

Investor Presentation

HY24 / results presentation↗

Media Release

HY24 / media release↗

Results Announcement

HY24 / results announcement↗

Prior comparable period

Notice of Half Year Result Announcement

HY23 / financial report↗

Full-year context

Media Release

FY23 / financial report↗

Results Announcement

FY23 / results announcement↗

Release context

CEO Address

HY24 / commentary↗

Chair Address

HY24 / commentary↗

Presentation

HY24 / commentary↗

Related insights

Cross-company views selected from the metrics in this briefing.

Earnings quality and statutory distortions

PBT and NPAT growth diverged by 46.2pp, with a distortion flag in the result.

→

Leverage and balance-sheet risk

Net debt / EBITDA is 16.20x, +9.40x versus the prior comparable period.

→

Revenue growth context

Revenue growth was -24.0% for this reporting period.

→

Cash conversion quality

This result converted 127.6% of EBITDA to operating cash flow.

→
This briefing is based on available company filings and standard Annolyse calculations. It is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.

Get notified when OCA publishes next

Get the next Oceania Healthcare briefing and related NZX reporting-season updates by email.